ABX-CRO

ABX-CRO

Dresden, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

ABX-CRO is a specialized German CRO with over two decades of experience, focusing on high-complexity areas like radiopharmaceuticals, molecular imaging, and translational medicine in oncology and neuroscience. It has built a global service portfolio through strategic acquisitions and regulatory registrations, recently expanding into the US and India. The company's core value proposition is its ability to navigate the intricate regulatory and technical challenges of imaging-based and radiopharmaceutical drug development from bench to bedside.

OncologyNeuroscience

Technology Platform

Integrated translational medicine platform specializing in molecular imaging (PET, SPECT, MRI, CT), radiopharmaceutical development (radiolabelling, GMP production, dosimetry), and a global network of preclinical and clinical research partners.

Opportunities

Significant growth in the radiopharmaceutical theranostics market and increased use of complex imaging biomarkers in clinical trials create strong demand for specialized CRO services.
Strategic expansion into the US and India provides access to large, growing pharmaceutical markets and global trial networks.

Risk Factors

Revenue is subject to client concentration and the success of their drug programs.
High regulatory scrutiny in radiopharmaceuticals and imaging trials poses operational and reputational risk.
Competition from larger CROs expanding into niche specialties and integration challenges from recent acquisitions are ongoing concerns.

Competitive Landscape

ABX-CRO competes in a specialized segment of the broader CRO market. It faces competition from large, full-service global CROs (e.g., IQVIA, Parexel) that have imaging divisions, as well as other niche imaging-focused CROs (e.g., BioClinica, now part of Labcorp). Its differentiation lies in its deep, two-decade focus on radiopharmaceuticals and translational imaging in oncology and CNS.